Everand Logo

Welcome to Everand!

  • STAT

    LISTEN: Watson’s latest stumble, a glimpse into the crystal ball, and revisiting Sarepta

    What will become of biotech in 2019? What's the legacy of Sarepta Therapeutics? And how do you say "overhyped" in Mandarin?
    by Damian Garde and Rebecca Robbins and Adam Feuerstein Dec 20, 2018 1 minute

    What will become of biotech in 2019? What’s the legacy of Sarepta Therapeutics? And how do you say “overhyped” in Mandarin?

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min readCrime & Violence
    STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
    A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

    Related Books & Audiobooks